Viscosupplementation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Single Injection, Three Injection, Five Injection), By End Use (Hospitals, Orthopedic Clinics/ASCs) By Region, By Competition Forecast & Opportunities, 2018-2028F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationViscosupplementation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Single Injection, Three Injection, Five Injection), By End Use (Hospitals, Orthopedic Clinics/ASCs) By Region, By Competition Forecast & Opportunities, 2018-2028F
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD4.03 billion |
| CAGR (2023-2028) | 8.29% |
| Fastest Growing Segment | Hospitals |
| Largest Market | North America |
Market Overview
Key Market Drivers
Rising Aging Population
Minimally Invasive Treatment
Increasing Sports Injuries
Patient Preference
Key Market Challenges
High Treatment Cost
Regulatory Challenges
Key Market Trends
Biocompatible Hyaluronic Acid (HA) Derivatives
Single-Injection Viscosupplements
Segmental Insights
Product Insights
End Use Insights
Regional Insights
In 2022, the Asia Pacific region led the market with the largest market share. This was primarily driven by the presence of a significant geriatric population, which is particularly susceptible to osteoarthritis, a key factor contributing to market growth in this region. Additionally, various initiatives aimed at strengthening the market have further fueled its expansion. For example, in April 2022, Juniper Biologics and Kolon Life entered into a licensing agreement for the development and commercialization of TissueGene-C low dose, an investigational therapy for knee osteoarthritis. This therapy is administered as a single intra-articular injection and eliminates the need for surgery. Under the agreement, Juniper is responsible for developing and marketing this gene therapy to medical professionals and hospitals in the Asia Pacific region.
Recent Developments
- In April 2022, Juniper Biologicssigned a licensing deal with Kolon Life Sciences to develop and commercialize, TissueGene-C low dose (TG-C LD), non-surgical investigational therapy administered asa single intra-articular injection, to treat knee osteoarthritis. Under thelicensing deal, Juniper will develop and market gene therapy to medicalprofessionals and hospitals in Asia-Pacific, the Middle East, and Africa.
- In May 2021, Ono PharmaceuticalCo., Ltd. and Seikagaku Corporation launched JOYCLU 30mg intra-articularinjection, a joint function improvement agent, for which Seikagaku received themanufacturing and marketing approval, in Japan, in March 2021.
Key Market Players
- Sanofi SA
- SeikagakuCorporation
- Smith& Nephew PLC.
- LifecoreBiomedical, LLC.
- FidiaFarmaceutici S.p.A
- F.Hoffmann-LaRoche Ltd.
- LGLife Sciences Ltd.
- FerringPharmaceutical B.V.
- ZimmerBiomet Holdings Inc
- AnikaTherapeutics, Inc.
| By Product Type | By End Use | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy